Table 1.
Clinical characteristics of flares post SARS-CoV-2 immunization
| Total | 20a | |
|---|---|---|
| Age-years | 38.65 ± 14.13 | |
| Sex-no. (%) | ||
|
Female Male |
18 (90%) 2 (10%) |
|
| Length of illness (SLE)-years | 7.04 ± 4.85 | |
| SLE treatmentb | ||
|
Prednisone Hydroxychloroquine azathioprine Mycophenolate Methotrexate Leflunomide No treatment |
16 (80%) 11 (55%) 10 (50%) 3 (15%) 3 (15%) 1 (5%) 3 (15%) |
|
| SLE outbreak in the past 6 months | 8 (40%) | |
| Confirmed COVID-19 history | 13 (65%) | |
| Flare episodes after immunization | ||
|
1st dose 2nd dose 1st and 2nd doses |
9 (45%) 18 (90%) 7 (35%) |
|
| Type of flare | 1era dosis | 2da dosis |
|
Arthritis Malar erythema Alopecia Lupus pneumonitis leukopenia Myopericarditis |
6 (30%) 1 (5%) - 1 (5%) 1 (5%) 1 (5%) |
17 (85%) 4 (20%) 1 (5%) - - - |
| Hospitalization for flare | 2 | |
a20 patients presented post-immunization flare; however, there were 27 flare episodes (given that 7 patients had flare episodes in the 1st and 2nd doses)
b15 patients use 2 or more drugs